Surviving cancer is an enormous achievement—but for many survivors, the end of active treatment does not mean a return to full function. Chemotherapy, radiation, and surgical interventions can leave lasting damage that persists for months or years after treatment concludes. Cognitive impairment, profound fatigue, and peripheral neuropathy are among the most common and disabling post-treatment consequences, and together they can make sustained employment genuinely impossible. SSDI is available not only during active cancer treatment but also when the lasting effects of that treatment prevent a return to work.
Understanding the Disabling Effects of Cancer Treatment
The three most common post-treatment impairments that support SSDI claims are:
- Chemotherapy-related cognitive impairment (“chemo brain”):Difficulty with memory, word retrieval, concentration, and processing speed that can significantly impair a survivor’s ability to perform even sedentary cognitive work
- Cancer-related fatigue:A persistent, overwhelming exhaustion unrelieved by rest that differs fundamentally from ordinary tiredness and frequently prevents survivors from sustaining a full workday or maintaining a consistent schedule
- Peripheral neuropathy:Nerve damage causing numbness, tingling, burning pain, and weakness in the hands and feet, which can limit fine motor tasks, standing, walking, and the ability to feel sensations needed for safe job performance
Each of these conditions can be independently disabling. When they occur together—as they frequently do in survivors of chemotherapy-intensive treatment—their combined functional impact is often severe.
Documenting Post-Treatment Disability
One challenge in these claims is that once active cancer treatment ends, medical follow-up may become less frequent, creating gaps in the record that adjudicators sometimes interpret as evidence of recovery. Proactive documentation is essential:
- Oncologist recordsshould explicitly address lasting treatment effects and their impact on functional capacity
- Neurological evaluationsdocumenting peripheral neuropathy, including nerve conduction studies that quantify the degree of nerve damage
- Neuropsychological testingto objectively document cognitive deficits beyond what informal clinical observation captures
- Fatigue assessmentsfrom treating providers that describe the severity, consistency, and functional impact of cancer-related fatigue
- Functional capacity assessmentsaddressing specific work-related limitations including sitting, standing, walking, lifting, and the ability to concentrate and maintain pace throughout a workday
The SSA’s Evaluation of Cancer Survivors
The SSA’s cancer listings address active malignancies and certain recurrent or metastatic conditions. Survivors whose cancer is in remission may not meet a listing, shifting the analysis to residual functional capacity. In these cases, the cumulative effect of multiple post-treatment impairments—cognitive, fatigue-related, and neuropathic—must be fully captured in the RFC to reflect the claimant’s true functional ceiling.
Vocational experts at hearings frequently acknowledge that significant limitations in concentration, pace, and attendance—combined with restrictions on hand use from neuropathy—would eliminate most categories of competitive employment. Ensuring the medical record supports these specific functional restrictions is the most important step in a post-treatment SSDI claim.
If you are a cancer survivor whose lasting treatment effects have prevented you from returning to work, PLBH can help you build the medical and functional record needed to support a successful SSDI claim. Call (800) 435-7542 to speak with a Social Security disability attorney today.